PROCEPT BioRobotics/$PRCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About PROCEPT BioRobotics
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Ticker
$PRCT
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
756
ISIN
US74276L1052
Website
PRCT Metrics
BasicAdvanced
$3.3B
-
-$1.70
1.09
-
Price and volume
Market cap
$3.3B
Beta
1.09
52-week high
$96.70
52-week low
$47.04
Average daily volume
773K
Financial strength
Current ratio
8.947
Quick ratio
7.596
Long term debt to equity
20
Total debt to equity
21.023
Interest coverage (TTM)
-24.00%
Profitability
EBITDA (TTM)
-91.045
Gross margin (TTM)
62.71%
Net profit margin (TTM)
-36.20%
Operating margin (TTM)
-38.70%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-13.36%
Return on equity (TTM)
-27.62%
Valuation
Price to revenue (TTM)
12.621
Price to book
8.36
Price to tangible book (TTM)
8.37
Price to free cash flow (TTM)
-35.645
Free cash flow yield (TTM)
-2.81%
Free cash flow per share (TTM)
-166.11%
Growth
Revenue change (TTM)
59.36%
Earnings per share change (TTM)
-19.91%
3-year revenue growth (CAGR)
81.77%
3-year earnings per share growth (CAGR)
-11.47%
What the Analysts think about PRCT
Analyst ratings (Buy, Hold, Sell) for PROCEPT BioRobotics stock.
Bulls say / Bears say
PROCEPT BioRobotics reported a 57% increase in total revenue for Q4 2024 compared to the prior year, indicating strong market demand for its products. (procept-biorobotics.com)
The company achieved a gross margin of 64% in Q4 2024, up from 49% in the same period the previous year, reflecting improved operational efficiency. (procept-biorobotics.com)
FDA clearance of the HYDROS™ Robotic System in August 2024 positions the company to capture additional market share with its next-generation technology. (procept-biorobotics.com)
Despite revenue growth, PROCEPT BioRobotics reported a net loss of $18.9 million in Q4 2024, indicating ongoing profitability challenges. (procept-biorobotics.com)
Operating expenses increased to $63.4 million in Q4 2024, up from $50.8 million in the prior year period, which may pressure future profitability. (procept-biorobotics.com)
An acute saline shortage in Q4 2024 led to a delay or cancellation of 10-20% of Aquablation procedures, potentially impacting future revenue streams. (procept-biorobotics.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
PRCT Financial Performance
Revenues and expenses
PRCT Earnings Performance
Company profitability
PRCT News
AllArticlesVideos
PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June
GlobeNewsWire·2 months ago
PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
GlobeNewsWire·3 months ago
PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PROCEPT BioRobotics stock?
PROCEPT BioRobotics (PRCT) has a market cap of $3.3B as of July 11, 2025.
What is the P/E ratio for PROCEPT BioRobotics stock?
The price to earnings (P/E) ratio for PROCEPT BioRobotics (PRCT) stock is 0 as of July 11, 2025.
Does PROCEPT BioRobotics stock pay dividends?
No, PROCEPT BioRobotics (PRCT) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next PROCEPT BioRobotics dividend payment date?
PROCEPT BioRobotics (PRCT) stock does not pay dividends to its shareholders.
What is the beta indicator for PROCEPT BioRobotics?
PROCEPT BioRobotics (PRCT) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.